Canaan Partners VII’s Tobira Therapeutics, Inc. Common Stock TBRA Stock Holding History

Canaan Partners VII’s Portfolio TBRA Stock Details TBRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-23,806	Closed	-$195K	–	4
2016 Q1	$195K	Hold	23,806	–	–	0.08%	4
2015 Q4	$239K	Hold	23,806	–	–	0.07%	4
2015 Q3	$230K	Sell	23,806 -586,628	-96%	-$8.23M	0.05%	4
2015 Q2	$10.5M	Buy	+610,434	New	+$8.93M	2.06%	4

Other funds holding TBRA

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Canaan Partners VII's TBRA Position: Q2 2016 in Review

Canaan Partners VII sold out of Tobira Therapeutics, Inc. Common Stock (TBRA) in Q2 2016, closing a stake of 23,806 shares — an estimated $195K sold.

Canaan Partners VII first reported a position in TBRA in Q2 2015 and held it in 4 quarters. The position peaked at $10.5M in Q2 2015. 45 funds tracked by Wall St. Rank hold TBRA as of Q2 2016.

Canaan Partners VII reported no remaining Tobira Therapeutics, Inc. Common Stock position as of Q2 2016 after selling out during the quarter.
Canaan Partners VII sold 23,806 Tobira Therapeutics, Inc. Common Stock shares in Q2 2016, an estimated $195K.
Canaan Partners VII first reported a position in Tobira Therapeutics, Inc. Common Stock in Q2 2015 and held it in 4 quarters.
Canaan Partners VII's Tobira Therapeutics, Inc. Common Stock position peaked at $10.5M in Q2 2015.
45 funds tracked by Wall St. Rank held Tobira Therapeutics, Inc. Common Stock as of Q2 2016.

Based on Canaan Partners VII's 13F filing for Q2 2016, filed 6 Jul 2016.